The acceptance of the compliance plan by Nasdaq is a positive development for INSE, indicating regulatory leniency and giving the company time to address its reporting issues. However, the need to restate financial statements and the delay in filing could raise concerns among investors about the reliability of past financial reports and the company's internal controls. This mixed impact suggests a neutral short-term price direction, as the market may weigh the positive aspect of regulatory compliance against the potential negative implications of the financial restatements.